Positive News SentimentPositive NewsNASDAQ:NGNE Neurogene (NGNE) Stock Price, News & Analysis $22.72 -0.09 (-0.39%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$22.82 +0.10 (+0.44%) As of 07/25/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Neurogene Stock (NASDAQ:NGNE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Neurogene alerts:Sign Up Key Stats Today's Range$22.01▼$23.1750-Day Range$14.95▼$23.0952-Week Range$6.88▼$74.49Volume75,610 shsAverage Volume194,481 shsMarket Capitalization$323.99 millionP/E RatioN/ADividend YieldN/APrice Target$46.17Consensus RatingModerate Buy Company Overview Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York. Read More Neurogene Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreNGNE MarketRank™: Neurogene scored higher than 67% of companies evaluated by MarketBeat, and ranked 308th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNeurogene has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageNeurogene has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Neurogene's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Neurogene are expected to grow in the coming year, from ($4.27) to ($4.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurogene is -5.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurogene is -5.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeurogene has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Neurogene's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.81% of the float of Neurogene has been sold short.Short Interest Ratio / Days to CoverNeurogene has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Neurogene has recently decreased by 1.78%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeurogene does not currently pay a dividend.Dividend GrowthNeurogene does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted18.81% of the float of Neurogene has been sold short.Short Interest Ratio / Days to CoverNeurogene has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Neurogene has recently decreased by 1.78%, indicating that investor sentiment is improving. News and Social Media3.2 / 5News Sentiment1.82 News SentimentNeurogene has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.09 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Neurogene this week, compared to 3 articles on an average week.MarketBeat Follows3 people have added Neurogene to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Neurogene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $102,975.00 in company stock.Percentage Held by InsidersOnly 9.92% of the stock of Neurogene is held by insiders.Percentage Held by Institutions52.37% of the stock of Neurogene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neurogene's insider trading history. Receive NGNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurogene and its competitors with MarketBeat's FREE daily newsletter. Email Address NGNE Stock News HeadlinesNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 5, 2025 | morningstar.comMNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business WireJuly 5, 2025 | businesswire.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move. | Porter & Company (Ad)Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 3, 2025 | businesswire.comNeurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome - MorningstarJuly 2, 2025 | morningstar.comMNeurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome - Business WireJuly 2, 2025 | businesswire.comStifel maintient sa recommandation d’achat sur l’action NeurogeneJuly 2, 2025 | fr.investing.comLa FDA approuve le design d’essai clinique de Neurogene pour sa thérapie génique contre le syndrome de RettJune 30, 2025 | fr.investing.comSee More Headlines NGNE Stock Analysis - Frequently Asked Questions How have NGNE shares performed this year? Neurogene's stock was trading at $22.86 on January 1st, 2025. Since then, NGNE shares have decreased by 0.6% and is now trading at $22.72. How were Neurogene's earnings last quarter? Neurogene Inc. (NASDAQ:NGNE) issued its earnings results on Friday, May, 9th. The company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($1.05) by $0.03. Who are Neurogene's major shareholders? Top institutional shareholders of Neurogene include Blair William & Co. IL (0.93%). Insiders that own company stock include Samsara Biocapital Gp, Llc, Rachel Mcminn, Christine Mikail Cvijic and Stuart Cobb. View institutional ownership trends. How do I buy shares of Neurogene? Shares of NGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Neurogene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neurogene investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE) and Disc Medicine (IRON). Company Calendar Last Earnings5/09/2025Today7/27/2025Next Earnings (Estimated)8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NGNE Previous SymbolNASDAQ:NGNE CIK1404644 Webwww.neurogene.com Phone(877) 237-5020Fax778-331-4486Employees90Year FoundedN/APrice Target and Rating Average Price Target for Neurogene$46.17 High Price Target$72.00 Low Price Target$24.00 Potential Upside/Downside+103.2%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($4.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$75.14 million Net MarginsN/A Pretax Margin-8,742.70% Return on Equity-36.16% Return on Assets-32.51% Debt Debt-to-Equity RatioN/A Current Ratio21.03 Quick Ratio21.03 Sales & Book Value Annual Sales$925 thousand Price / Sales350.31 Cash FlowN/A Price / Cash FlowN/A Book Value$20.89 per share Price / Book1.09Miscellaneous Outstanding Shares14,262,000Free Float12,602,000Market Cap$324.03 million OptionableOptionable Beta1.51 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:NGNE) was last updated on 7/28/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA grave, grave error.Nvidia just hit $4 trillion… but a tech apocalypse may already be underway. A controversial new documentary...Porter & Company | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.